Fig. 3From: Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancerGenomic alterations identified in NSCLC patients at resistance to TKIs. Frequency of genomic alterations in paired samples of MET-TKI-treated (a) or EGFR-TKI-treated (b) NSCLC patients. Each column represents one patient. The clinical characteristics of patients are shown at the top. The frequency of each gene alteration pre- and post-treatment is listed to the left of the heatmapBack to article page